Top of page Skip navigation

13 July 

13.00: Welcome Keynotes – Sustaining a Biotech Ecosystem

Session Sponsor:

Tim Schoen
, BioMed Realty
Glenn Crocker

Andy Neely, University of Cambridge
Mike Snowden, AstraZeneca

14.30: Transforming R&D with Patients

The patients we all are, are invaluable resources to improve the way we approach R&D. This session will highlight some examples of this and how patients are being placed at the heart of R&D.


Lachlan Hay, Clinuvel
panelist tbc, Cambridge Rare Disease Network

15.30: The Business Models of Research

New modalities, sophistication of data health claims, global and more complex markets and Pharma business models are evolving but what about their R&D models? What will be key to lead tomorrow’s therapeutics development? And importantly who will take the lead? This panel session will discuss some of the key considerations on:

  • Strategic approaches in therapeutic areas from niche to cross indications
  • The specialisation in technological elements and how data is taking a leading role in R&D
  • New modalities of development


Jeremy Carmichael, Astex Therapeutics
Kath Mackay, Alderley Park
Nicholas Dolman, ThermoFisher
Guy Hill, Trajecture

16.30:  Biotech Rising Stars

Listen to exciting early stage companies and their technology is revolutionising the biotech game. The session will see presentations from the StartCodon and Illumina accelerator programmes.

Presentations from:

Dristhi Discoveries
Enhanc3d Genomics


14 July

Transforming Treatments with Diagnostics

With the promise for earlier interventions and better patients’ segmentation, diagnostics have the potential to disturb the way therapeutics are delivered. This session will showcase three examples of areas where diagnostics can disturb therapeutics.


Lisa Baldwin, CEIDR Innovations
Michael Hornberger, Norwich Medical School, UEA

Speaker tbc, Inivata

10.00: Unlocking the Undruggable Space

A session to review current limitations in targets addressed and presentations on solutions to unlock them.


Benedict Cross, Phoremost
Kamil Tamiola, Peptone

Laura Itzhaki, Polyprox

11.00: Surpassing Current Preclinical Models

A session to review the current advances and limitations of innovative pre-clinical models.


Spencer Thomas, National Physical Laboratory
David Hughes, CN Bio

12.00: Manufacturing New Modalities

A session to review what will be needed to shift paradigm in therapeutics development especially in the cell and gene therapy space


Sharon Brownlow, Cell and Gene Therapy Catapult
Jason Jones, Oribiotech

Jose Castillo, Univercells

13.00Mobilising the response to the novel coronavirus SARS-CoV-2 outbreak and spread - Global Challenges

14.00Mobilising the response to the novel coronavirus SARS-CoV-2 outbreak and spread - Diagnostics Tools

15.00Mobilising the response to the novel coronavirus SARS-CoV-2 outbreak and spread - Therapeutics


 Jane Osbourn

 16.00: Closing Keynote Session

Akshay Vaishnaw, President Research and Development, Alnylam
Alejandra Solache, Vice President New Product Development, Abcam

Headline Sponsor


Media Sponsor